Alliance For Cancer Gene Therapy Inc
EIN: 61619523 · Stamford, CT · NTEE: T30
| Metric | Value |
|---|---|
| Total Revenue | $6.5M |
| Total Expenses | $2.5M |
| Net Assets | $6.3M |
Is Alliance For Cancer Gene Therapy Inc Legit?
Insufficient Data
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
About Alliance For Cancer Gene Therapy Inc
Alliance For Cancer Gene Therapy Inc (EIN: 61619523) is a nonprofit organization based in Stamford, CT, classified under NTEE code T30. The organization reported total revenue of $6.5M and total assets of $15.7M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alliance For Cancer Gene Therapy Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Alliance For Cancer Gene Therapy Inc is a mid-size nonprofit that has been operating for 25 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 4.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $3.2M |
| Total Expenses | $2.5M |
| Surplus / Deficit | +$733K |
| Total Assets | $7.9M |
| Total Liabilities | $1.7M |
| Net Assets | $6.3M |
| Operating Margin | 22.7% |
| Debt-to-Asset Ratio | 21.1% |
| Months of Reserves | 38.1 months |
Financial Health Grade: A
In 2023, Alliance For Cancer Gene Therapy Inc reported a surplus of $733K with revenue exceeding expenses, holds 38.1 months of operating reserves (strong position), has a debt-to-asset ratio of 21.1% (moderate leverage).
Financial Trends
Over 13 years of filings (2011–2023), Alliance For Cancer Gene Therapy Inc's revenue has grown at a compound annual growth rate (CAGR) of 4.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -1.9% | +38.5% | +13.0% |
| 2022 | +92.0% | -30.2% | +2.4% |
| 2021 | -25.4% | +35.5% | +10.5% |
| 2020 | +80.8% | +5.2% | -2.4% |
| 2019 | -6.0% | +13.5% | -3.4% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2001 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Analysis Pending
AI enrichment for Alliance For Cancer Gene Therapy Inc has not yet been completed. Basic IRS 990 data is shown below. Check back later for a full transparency report including a Mission Score, spending breakdown, executive compensation analysis, and red flags assessment.
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Alliance For Cancer Gene Therapy Inc with a Mission Score of 0 out of 100 (Very Poor). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $733K, with revenue exceeding expenses.
- Debt-to-asset ratio: 21.1%.
Frequently Asked Questions about Alliance For Cancer Gene Therapy Inc
Is Alliance For Cancer Gene Therapy Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Alliance For Cancer Gene Therapy Inc (EIN: 61619523) insufficient data. 0 red flags identified, 0 strengths noted.
How does Alliance For Cancer Gene Therapy Inc spend its money?
Detailed spending breakdown data is not yet available for Alliance For Cancer Gene Therapy Inc. Check back for updated IRS 990 analysis.
Are donations to Alliance For Cancer Gene Therapy Inc tax-deductible?
Alliance For Cancer Gene Therapy Inc is registered as a tax-exempt nonprofit (EIN: 61619523). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Where is Alliance For Cancer Gene Therapy Inc located?
Alliance For Cancer Gene Therapy Inc is headquartered in Stamford, Connecticut and files with the IRS under EIN 61619523. It is classified under NTEE code T30.
How many years of IRS 990 filings does Alliance For Cancer Gene Therapy Inc have?
Alliance For Cancer Gene Therapy Inc has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $6.5M in total revenue.
Filing History
IRS 990 filing history for Alliance For Cancer Gene Therapy Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Alliance For Cancer Gene Therapy Inc's revenue has grown by 60.9%, moving from $2.0M to $3.2M. Total assets increased by 81.6% over the same period, from $4.4M to $7.9M. Total functional expenses rose by 22.1%, from $2.0M to $2.5M. In its most recent filing year (2023), Alliance For Cancer Gene Therapy Inc reported a surplus of $733K, with revenue exceeding expenses. The organization holds $1.7M in liabilities against $7.9M in assets (debt-to-asset ratio: 21.1%), resulting in net assets of $6.3M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $3.2M | $2.5M | $7.9M | $1.7M | — | View 990 |
| 2022 | $3.3M | $1.8M | $7.0M | $1.2M | — | View 990 |
| 2021 | $1.7M | $2.6M | $6.9M | $1.8M | — | View 990 |
| 2020 | $2.3M | $1.9M | $6.2M | $1.6M | — | View 990 |
| 2019 | $1.3M | $1.8M | $6.4M | $1.9M | — | View 990 |
| 2018 | $1.4M | $1.6M | $6.6M | $1.8M | — | View 990 |
| 2017 | $1.6M | $873K | $6.0M | $1.5M | — | View 990 |
| 2016 | $1.3M | $1.5M | $5.1M | $1.8M | — | View 990 |
| 2015 | $1.4M | $1.7M | $5.0M | $1.2M | — | View 990 |
| 2014 | $1.2M | $773K | $4.7M | $750K | — | View 990 |
| 2013 | $933K | $815K | $4.4M | $1.1M | — | View 990 |
| 2012 | $2.5M | $1.1M | $4.4M | $1.4M | — | View 990 |
| 2011 | $2.0M | $2.0M | $4.4M | $2.8M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $3.2M, expenses of $2.5M, and assets of $7.9M (revenue -1.9% year-over-year).
- 2022: Revenue of $3.3M, expenses of $1.8M, and assets of $7.0M (revenue +92.0% year-over-year).
- 2021: Revenue of $1.7M, expenses of $2.6M, and assets of $6.9M (revenue -25.4% year-over-year).
- 2020: Revenue of $2.3M, expenses of $1.9M, and assets of $6.2M (revenue +80.8% year-over-year).
- 2019: Revenue of $1.3M, expenses of $1.8M, and assets of $6.4M (revenue -6.0% year-over-year).
- 2018: Revenue of $1.4M, expenses of $1.6M, and assets of $6.6M (revenue -16.5% year-over-year).
- 2017: Revenue of $1.6M, expenses of $873K, and assets of $6.0M (revenue +28.8% year-over-year).
- 2016: Revenue of $1.3M, expenses of $1.5M, and assets of $5.1M (revenue -7.6% year-over-year).
- 2015: Revenue of $1.4M, expenses of $1.7M, and assets of $5.0M (revenue +15.4% year-over-year).
- 2014: Revenue of $1.2M, expenses of $773K, and assets of $4.7M (revenue +26.9% year-over-year).
- 2013: Revenue of $933K, expenses of $815K, and assets of $4.4M (revenue -62.6% year-over-year).
- 2012: Revenue of $2.5M, expenses of $1.1M, and assets of $4.4M (revenue +24.3% year-over-year).
- 2011: Revenue of $2.0M, expenses of $2.0M, and assets of $4.4M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Alliance For Cancer Gene Therapy Inc:
Data Sources and Methodology
This transparency report for Alliance For Cancer Gene Therapy Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.